CXCL8 and head and neck cancer: A phase III clinical trial demonstrated that elevated CXCL8 levels were associated with OS irrespective of treatment in locoregionally advanced head and neck cancer; however, tirapazamine/cisplatin treatment seemed to be beneficial for patients with high CXCL8 36.